In the BioHarmony Drug Report Database
Barhemsys, Solian (amisulpride) is a small molecule pharmaceutical. Amisulpride was first approved as Barhemsys on 2020-02-26. The pharmaceutical is active against D(2) dopamine receptor and D(3) dopamine receptor. Barhemsys, solian’s patent is valid until 2031-03-10 (FDA).
Image (chem structure or protein)